Loading...
XSHG600557
Market cap1.10bUSD
Dec 24, Last price  
14.13CNY
1D
0.71%
1Q
9.62%
Jan 2017
-16.54%
Name

Jiangsu Kanion Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600557 chart
P/E
14.99
P/S
1.65
EPS
0.94
Div Yield, %
1.60%
Shrs. gr., 5y
-0.49%
Rev. gr., 5y
4.95%
Revenues
4.87b
+11.88%
560,144,477802,419,230852,699,626998,634,6671,132,031,391968,532,6931,358,307,6491,537,777,5981,903,373,7022,230,302,8672,562,928,2432,820,446,2843,000,277,8073,274,698,1533,823,804,7354,565,798,0043,031,926,3563,648,570,0844,350,871,9224,867,806,702
Net income
537m
+23.54%
47,231,17248,844,62264,022,58596,357,706141,940,085160,268,157180,728,871182,508,139239,671,216297,017,573319,614,208362,336,257373,740,970373,782,724431,386,148506,993,260262,922,648320,543,630434,467,433536,732,878
CFO
1.06b
+6.01%
21,682,080101,436,378108,980,98392,733,80658,389,0790166,399,11490,186,765212,108,112388,106,244311,543,597514,795,720299,017,699382,928,707636,392,894925,725,534701,103,454908,295,889995,939,9921,055,799,495
Dividend
May 31, 20240.37203 CNY/sh

Profile

Jiangsu Kanion Pharmaceutical Co.,Ltd. researches and develops, produces, and sells Chinese medicines. It offers medicines in the fields of gynecology, orthopedics, antiviral, cardio cerebrovascular, and other fields. The company was founded in 1975 and is based in Lianyungang, China.
URL
https://www.kanion.com/
IPO date
Sep 18, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,867,807
11.88%
4,350,872
19.25%
3,648,570
20.34%
Cost of revenue
4,141,270
3,770,944
3,168,714
Unusual Expense (Income)
NOPBT
726,537
579,928
479,856
NOPBT Margin
14.93%
13.33%
13.15%
Operating Taxes
3,932
3,799
3,916
Tax Rate
0.54%
0.66%
0.82%
NOPAT
722,604
576,129
475,940
Net income
536,733
23.54%
434,467
35.54%
320,544
21.92%
Dividends
(128,506)
Dividend yield
1.09%
Proceeds from repurchase of equity
1,053
BB yield
-0.01%
Debt
Debt current
11,860
234,500
Long-term debt
1,925
1,925
Deferred revenue
126,155
78,780
90,518
Other long-term liabilities
1,925
1,925
1,925
Net debt
(2,444,592)
(1,757,514)
(877,013)
Cash flow
Cash from operating activities
1,055,799
995,940
908,296
CAPEX
(297,481)
Cash from investing activities
(555,102)
Cash from financing activities
(129,812)
FCF
841,969
954,244
861,929
Balance
Cash
2,429,273
1,771,300
1,113,438
Long term investments
15,319
Excess cash
2,201,202
1,553,756
931,010
Stockholders' equity
5,300,762
4,919,803
4,484,819
Invested Capital
3,307,432
3,382,285
3,820,351
ROIC
21.60%
16.00%
11.88%
ROCE
13.19%
11.75%
10.10%
EV
Common stock shares outstanding
577,132
576,315
576,429
Price
20.52
9.44%
18.75
53.19%
12.24
20.35%
Market cap
11,842,751
9.60%
10,805,904
53.16%
7,055,490
17.01%
EV
9,585,915
9,228,187
6,346,825
EBITDA
913,556
769,759
666,860
EV/EBITDA
10.49
11.99
9.52
Interest
1,457
1,914
11,153
Interest/NOPBT
0.20%
0.33%
2.32%